Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series B financing round, led by Hongfeng Venture. Additional investors included Oriental Wisdom Capital, Zhongchuang Yongjian (Ningbo) Venture Capital, and existing investor Qiao Jing Capital. The funds will be directed towards Phase I clinical studies for its best-in-class bispecific antibodies (BsAbs) Bis2 and Bis5, as well as a pre-clinical study for a first-in-class tri-specific antibody.
Focus on Innovative Antibody Platforms
L&L Biopharma specializes in developing innovative, differentiated bispecific and multi-specific antibodies. Its platforms include PD-1-targeted, monoclonal, bispecific, and multi-specific antibody discovery platforms, an antibody sequence discovery platform, computer modeling humanization technology platform, sequence-specific IgG-like dual, multispecific antibody (SBody) platform, and an efficient engineering cell line platform.
Clinical Trials and Core Products
The company’s core products, Bis5, a bispecific antibody targeting PD-1 and TIM3, and CD8/CLDN18.2 bispecific antibody Bis2, are currently undergoing Phase I clinical trials in China and the United States. This financing round will further support the advancement of these promising therapies, enhancing L&L Biopharma’s position in the tumor immunotherapy field.-Fineline Info & Tech
